NCT02900651 - Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies | Biotech Hunter

Enrollment

139

Participants

Timeline

Start Date

October 3, 2016

Primary Completion Date

October 9, 2024

Study Completion Date

October 9, 2024

Conditions

Diffuse Large B-cell Lymphoma

Interventions

DRUG

MAK683

Drug: MAK683

Trial Locations (16)

20089

Novartis Investigative Site, Rozzano

20133

Novartis Investigative Site, Milan

28041

Novartis Investigative Site, Madrid

50937

Novartis Investigative Site, Cologne

77030

Uni Of TX MD Anderson Cancer Cntr Dept of Onc, Houston

79106

Novartis Investigative Site, Freiburg im Breisgau

90404

UCLA Santa Monica Hematology Oncology, Santa Monica

94115

UCSF ., San Francisco

94800

Novartis Investigative Site, Villejuif

168583

Novartis Investigative Site, Singapore

200032

Novartis Investigative Site, Shanghai

610041

Novartis Investigative Site, Chengdu

M5G 2M9

Novartis Investigative Site, Toronto

Unknown

Novartis Investigative Site, Hong Kong

811-1395

Novartis Investigative Site, Fukuoka

411 8777

Novartis Investigative Site, Sunto Gun